Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FASN | P49327 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733674 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53HPGDLMNAFASN | |
| SCHEMBL14209216 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53HPGDLMNAFASN | |
| SCHEMBL4197739 | 0.89 | FASN (0.61) | ALDH1A1TP53HPGDFASN | |
| SCHEMBL16799271 | 0.89 | HPGD (0.50) | ALDH1A1TP53HPGDLMNAFASN | |
| SCHEMBL4191753 | 0.89 | PARP10 (0.58) | PARP10PARP14ALDH1A1TP53HPGD | |
| SCHEMBL4735211 | 0.89 | CA12 (0.58) | PARP10PARP14ALDH1A1TP53HPGD | |
| SCHEMBL14161774 | 0.88 | PARP10 (0.46) | PARP10PARP14ALDH1A1TP53HPGD | |
| SCHEMBL4731334 | 0.87 | FASN (0.63) | PARP10PARP14ALDH1A1HPGDLMNA | |
| SCHEMBL4735697 | 0.87 | LMNA (0.51) | PARP10ALDH1A1TP53HPGDLMNA | |
| SCHEMBL4195205 | 0.87 | ALDH1A1 (0.48) | ALDH1A1TP53HPGDLMNAFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075077-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | PARP10 810/4885PARP14 1992/4885ALDH1A1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.